SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------
FORM 10-Q
---------
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1999
OR
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission file number Q4823
ACME UNITED CORPORATION
-----------------------
(Exact name of registrant as specified in its charter)
CONNECTICUT 06-0236700
----------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
75 Kings Highway Cutoff, Fairfield, Connecticut 06430
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (203) 332-7330
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No |_|
Registrant had 3,377,488 shares outstanding as of May 14, 1999 of its $2.50 par
value Common Stock.
<PAGE 2>
ACME UNITED CORPORATION
Page
----
Part I -- FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets.......................... 3
Condensed Consolidated Statements of Operations
and Comprehensive Income (Loss)............................. 5
Condensed Consolidated Statements of Cash Flows................ 6
Notes to Condensed Consolidated Financial Statements........... 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations................................... 9
Part II -- OTHER INFORMATION
Item 1. Legal Proceedings................................................ 12
Item 2. Changes in Securities............................................ 12
Item 3. Defaults Upon Senior Securities.................................. 12
Item 4. Submission of Matters to a Vote of Security Holders.............. 12
Item 5. Other Information................................................ 12
Item 6. Exhibits and Reports on Form 8-K................................. 12
Signatures............................................................... 13
<PAGE 3>
<TABLE>
PART I. FINANCIAL INFORMATION
ACME UNITED CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(all amounts in thousands except share data)
March 31 December 31
1999 1998
------------ -----------
<CAPTION>
<S> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents................................. $ 549 $ 40
Accounts receivable, less allowance....................... 8,190 7,722
Inventories:
Finished goods......................................... 4,653 7,122
Work in process........................................ 810 1,240
Raw materials and supplies............................. 3,206 4,907
---------- ----------
8,669 13,269
Prepaid expenses and other current assets................. 1,206 424
---------- ----------
Total current assets.............................. 18,614 21,455
---------- ----------
Property, plant and equipment:
Land ..................................................... 203 219
Buildings................................................. 2,074 2,179
Machinery and equipment................................... 13,446 16,216
---------- ----------
15,723 18,614
Less accumulated depreciation............................. 10,117 12,573
---------- ----------
5,606 6,041
Other assets................................................ 906 895
Goodwill, less accumulated amortization..................... 394 505
---------- ----------
Total assets.................................... $ 25,520 $ 28,896
========== ==========
See notes to condensed consolidated financial statements.
<PAGE 4>
ACME UNITED CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS - continued
(UNAUDITED)
(all amounts in thousands except share data)
March 31 December 31
1999 1998
------------ -----------
LIABILITIES
Current Liabilities:
Notes payable ............................................ $ 853 $ 882
Accounts payable.......................................... 3,589 4,422
Other accrued liabilities................................. 5,011 3,590
Current portion of long term debt......................... 2,736 8,944
---------- ----------
Total current liabilities............................. 12,189 17,838
Long term debt, less current portion...................... 6,969 6,382
---------- ----------
Total liabilities.................................... 19,158 24,220
---------- ----------
STOCKHOLDERS' EQUITY
Common stock, par value $2.50 :
Authorized-4,000,000 shares;
issued-3,482,495 shares in 1999
and 1998, including treasury stock ..................... 8,706 8,706
Additional paid-in capital ............................... 2,233 2,233
Retained-earnings deficit................................. (2,623) (4,380)
Accumulated other comprehensive loss -
translation adjustment.................................. (1,306) (1,235)
Treasury stock, at cost -105,007 shares................... (648) (648)
---------- ----------
Total stockholders' equity............................ 6,362 4,676
---------- ----------
Total liabilities and stockholders' equity.......... $ 25,520 $ 28,896
========== ==========
</TABLE>
See notes to condensed consolidated financial statements.
<PAGE 5>
<TABLE>
ACME UNITED CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(all amounts in thousands, except per share amounts)
Three Months Ended
March 31
--------------------
1999 1998
-------- --------
<CAPTION>
<S> <C> <C>
Revenues:
Net sales................................................... $ 7,570 $ 8,471
Other income................................................ 177 53
-------- --------
Total revenues.......................................... 7,747 8,524
-------- --------
Costs and expenses:
Cost of goods sold.......................................... 6,077 6,531
Selling, general and administrative expenses................ 1,868 2,036
Interest expense............................................ 358 338
-------- --------
8,303 8,905
-------- --------
Loss from continuing operations before income tax benefit..... (556) (381)
Income tax benefit............................................ (14) (5)
-------- --------
Net loss from continuing operations........................... (542) (376)
Discontinued operations:
Gain on sale of discontinued operations..................... 2,101 ---
Income from discontinued operations......................... 198 284
-------- --------
2,299 284
-------- --------
Net income (loss)............................................. 1,757 (92)
Other comprehensive expense - foreign currency translation.... (71) (12)
-------- --------
Comprehensive income (loss)................................... $ 1,686 $ (104)
======== ========
Earnings (loss) per share:
Continuing operations....................................... $ (0.16) $ (0.11)
Discontinued operations..................................... 0.68 0.08
-------- --------
Net income (loss)........................................... $ 0.52 $ (0.03)
======== ========
Weighted average number of common shares
outstanding- denominator per share computations............. 3,377 3,368
</TABLE>
See notes to condensed consolidated financial statements.
<PAGE 6>
<TABLE>
ACME UNITED CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(all amounts in thousands)
Three Months Ended
March 31
--------------------
1999 1998
-------- --------
<CAPTION>
<S> <C> <C>
Operating activities:
Net income (loss)............................................... $ 1,757 $ (92)
Adjustments to reconcile net income to net cash used by
operating activities:
Gain on sale of discontinued operations...................... (2,101) ---
Depreciation.................................................. 236 263
Amortization.................................................. 3 6
Increase in deferred income taxes............................. --- 28
Gain on disposal of property, plant, and equipment............ --- (3)
Changes in operating assets and liabilities:
Accounts receivable......................................... (624) (410)
Inventories................................................. 1,743 255
Prepaid expenses and other current assets................... 140 (425)
Other assets................................................ (14) 3
Accounts payable............................................ (800) 869
Other accrued liabilities................................... (1,209) (692)
---------- ----------
Net cash used by operating activities..................... (869) (198)
---------- ----------
Investing activities:
Capital expenditures............................................ (242) (647)
Proceeds from sales of property, plant, and equipment........... --- 44
Proceeds from sale of discontinued operations.................. 7,156 ---
---------- ----------
Net cash provided (used) by investing activities............ 6,914 (603)
---------- ----------
Financing activities:
Proceeds from long-term debt and credit arrangements............ 1,786 767
Payments on long-term debt and credit arrangements.............. (7,321) ---
Stock options exercised......................................... --- 30
---------- ----------
Net cash (used) provided by financing activities............ (5,535) 797
---------- ----------
Effect of exchange rate changes on cash........................... (1) ---
---------- ----------
Net change in cash and cash equivalents .......................... 509 (4)
Cash and cash equivalents at beginning of period.................. 40 25
---------- ----------
Cash and cash equivalents at end of period........................ $ 549 $ 21
========== ==========
</TABLE>
See notes to condensed consolidated financial statements.
<PAGE 7>
Notes to CONDENSED CONSOLIDATED Financial Statements
(Unaudited)
Note 1 -- Basis of Presentation
In the opinion of management, the accompanying condensed consolidated
financial statements contain all adjustments necessary to present fairly the
financial position, results of operations and cash flows. However, the financial
statements do not include all of the disclosures normally required by generally
accepted accounting principles or those normally made in the Company's annual
report on Form 10-K. Please refer to the Company's annual report on Form 10-K
for the year ended December 31, 1998 for such disclosures. The condensed balance
sheet as of December 31, 1998 was derived from the audited financial statements
as of that date. The results of operations for the three months ended March 31,
1999 are not necessarily indicative of the results to be expected for the full
year.
Because the Company has a loss from continuing operations in the three
months ended March 31, 1999 and 1998, the weighted average number of stock
options outstanding were anti-dilutive and are excluded from the per share
calculations.
Note 2 -- Discontinued Operations
On March 22, 1999 the Company sold its medical business including customer
lists, inventory, and certain equipment for approximately $8,156,000 realizing a
gain of $2,101,000. The consolidated statements of operations for 1998 have been
reclassified to reflect the discontinuance of the medical business segment.
The consolidated statements of operations relating to the medical business
follow:
Three Months Ended
March 31
---------------------------
1999 1998
--------- ---------
Net sales.......................... $ 2,101,000 $ 2,574,000
Costs and expenses................. 1,903,000 2,290,000
---------- ----------
Income from operations............. $ 198,000 $ 284,000
========== ==========
Earnings per share................. $ .06 $ .08
========== ==========
Income taxes related to the medical business are not material. As of March
31, 1999, $1,000,000 due relating to the sale of the Medical business is
classified with prepaid expenses and other assets.
Note 3 -- Contingencies
The Company has been involved in certain environmental matters.
Additionally, the Company has been involved in numerous legal actions relating
to the use of certain latex products, which the Company distributes, but does
not manufacture. The Company is one of many defendants. The Company has been
released from the majority of the lawsuits. While a limited number of lawsuits
remain, they are still in preliminary stages and there is no indication the
Company's products were involved. Based on information available, the Company
believes that there will not be a material adverse impact on financial position,
results of operations, or liquidity, from environmental and product liabilities,
either individually or in aggregate.
<PAGE 8>
Notes to CONDENSED CONSOLIDATED Financial Statements- continued
(Unaudited)
Note 4 -- Debt
The company has short-term lines of credit for its foreign subsidiaries
which are renewable at various times throughout the remainder of 1999. The
aggregate amount available under these lines is $1,029,000 of which $853,000 is
outstanding at March 31, 1999.
Long term debt consisted of the following:
(all amounts in thousands)
March 31 December 31
1999 1998
------------ ------------
Notes payable:
Refinanced.................. $ 8,284 $ 6,614
Other....................... 1,421 8,712
---------- ----------
9,705 15,326
Less current portion 2,736 8,944
---------- ----------
$ 6,969 $ 6,382
========== ==========
On March 22, 1999, the Company used the proceeds from the sale of the
medical business to pay down $6,800,000 of outstanding debt.
On April 28, 1999 the Company refinanced its debt arrangements in the
U.S. and Canada. Under the new arrangement, the Company may borrow up to
$10,500,000 through November 15, 1999 and from January 1, 2000 to April 30, 2000
(the maturity date); between November 16, 1999 and December 31, 1999 the Company
may borrow up to $7,250,000. (The amounts the Company may borrow are based on a
formula which applies specific percentages to balances of accounts receivable
and inventories.) The Company expects to have a minimum of $4,800,000
outstanding under this arrangement through March 2000. In addition, the Company
converted $2,500,000 of debt into a term loan payable in monthly installments of
$50,000, plus interest commencing May 1, 1999 through April 1, 2000 and a final
installment of $1,900,000, plus interest, due April 30, 2000. All amounts
borrowed under these arrangements bear interest at the prime base rate, as
defined, plus 1.5%. The refinancing has been applied retroactively. On April 29,
1999, outstanding debt under the Company's arrangements in the U.S. and Canada
was $8,618,694 and $466,480 was available for additional borrowing.
Under these arrangements, the Company, among other things, is restricted
with respect to dividends, additional borrowings, investments, mergers,
distributions, and property and equipment acquisitions. Further, the Company is
required to maintain specific amounts of tangible net worth, as defined,
commencing June 30, 1999 and a specified debt service coverage ratio, as
defined, commencing September 30, 1999. The Company believes these financial
covenants will be met. Maturities of long-term debt as of March 31, 1999 which
reflect the refinancing are $2,735,602 through March 31, 2000 and $6,969,234
through March 31,2001. Substantially all assets are pledged as collateral for
debt, including that portion refinanced.
<PAGE 9>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
For the Three Months Ended March 31, 1999
Results of Operations
Net Sales
Traditionally, the Company's sales are stronger in the second and third
quarters, and weaker in the first and fourth quarters of the fiscal year due to
the seasonal nature of the business specific to the back-to-school season.
Consolidated net sales for the quarter ended March 31, 1999 were $7,570,000
compared with $8,471,000 for 1998, or 11% lower. In March 1999, the Company sold
its medical business to Medical Action Industries, Inc. In the quarter, efforts
were focused on building inventory to meet contractual obligations to sell
additional medical products to Medical Action Industries, Inc., which slowed
production and shipments of consumer products thereby negatively impacting
continuing operations. Domestic consumer sales backorder for the first quarter
of 1999 was $569,000 compared with $107,000 for the first quarter of 1998, or
four times higher. Had backorder levels been equal to prior year, sales would
have been only 5% lower.
Domestic sales growth occurred in first aid, manicure implements, and
geometry tools offsetting declines in all other categories.
International sales decreased by 14% for the first quarter. Net sales in
Canada were down 14%, of which 3% was due to currency fluctuations. The first
quarter of 1998 benefited from initial sales related to the acquisition of the
Rotex Division of Esselte Canada in December of 1997. Since the acquisition,
product rationalization of lower margin products, coupled with the loss of some
products sold to a customer negatively impacted the sales. European sales
decreased 14% mainly due to weak sales in the United Kingdom, as a slowing
economy negatively impacted results in the first quarter.
Gross Profit
The gross profit from continuing operations for the first quarter of 1999
was $1,492,000 (19.7% of net sales) compared with $1,940,000 (22.9% of net
sales) for the first quarter of 1998. Manufacturing inefficiencies negatively
impacted manufacturing costs in the U.S. consumer business which lead to a
decline in gross margin from 27.1% in 1998 to 20.3% in the first quarter of
1999. The international gross margin rose to 18.0% in the first quarter of 1999
from 15.1% in the comparable quarter in 1998. The gain in gross profit was
primarily due to savings associated with re-sourcing products acquired from
Esselte Canada in 1997.
Management expects to consolidate sourcing product from Asia to leverage
its buying power to improve margins.
<PAGE 10>
Selling, General and Administrative Expenses
Selling, general and administrative ("SG&A") expenses for the first quarter
of 1999 were $1,868,000 (25% of net sales) compared with $2,009,000 (24% of net
sales) for the same period of 1998, a decrease of $141,000, or 7%. The primary
reason for the decrease is staff reductions. Management is continuing to
investigate other potential SG&A cost saving programs.
Operating Results
Net income for the first quarter of 1999 is $1,757,000, or 52 cents per
share. Net income for the first quarter of 1999 includes a realized gain on the
sale of the medical business of $2,101,000. The net loss from continuing
operations for the first quarter of 1999 is $542,000, or 16 cents per share,
compared with net loss of $376,000, or 11 cents per share, for the first quarter
of 1998.
Financial Condition
Liquidity and Capital Resources
During the first three months of 1999, the total debt decreased by
$4,760,000 compared to total debt at December 31, 1998.
Cash generated from operating activities is expected to be sufficient to
meet debt maturities and fund capital expenditures through March 2000. The
Company's current credit arrangements coupled with cash expected from operating
activities are considered adequate to meet liquidity needs through then.
The Company's working capital, current ratio and long term debt to equity
ratio follow:
March 31, 1999 December 31, 1998
------------------ ------------------
Working capital...................... $6,425,709 $3,616,421
Current ratio........................ 1.53 to 1 1.20 to 1
Long-term debt to equity ratio....... 1.10 1.37
Year 2000
The Company has completed the assessment phase of its Year 2000
compliance program and is currently completing modifications and testing of its
information technology and other internal systems with the exception of Germany.
In Germany, the Company has selected a new financial system to mitigate a Year
2000 problem. The Company's goal is to complete implementation of this new
system by the end of the second quarter 1999. Financial systems at the Company's
other locations are substantially Year 2000 compliant.
The Company is in the process of gathering information about the Year
2000 compliance status of its significant suppliers and is developing a
contingency plan for alternative sourcing. The Company's goal is to complete its
Year 2000 compliance program by the end of the third quarter 1999.
Estimated future costs for the Year 2000 compliance program range from
$225,000 to $275,000 of which approximately $150,000 relates to Germany. Of
these costs, the Company expects that $75,000 will be charged to operations as
expenses. The costs of this project and its completion date are based on
management's best estimates, which were derived from numerous assumptions about
future events, including the availability of certain resources, third party
remediation plans, and other factors.
The Company continuously monitors its action plans addressing the Year
2000 issue, and is developing contingency plans to address unforeseen problems
and "worst case" scenarios. This is potentially a significant issue for most, if
not all, companies, with implications which can not be anticipated or predicted
with any degree of certainty.
<PAGE 11>
Safe Harbor for Forward-looking Statements
Forward-looking statements in this report, including without limitation,
statements related to the Company's plans, strategies, objectives, expectations,
intentions and adequacy of resources, are made pursuant to the safe harbor
provisions of the Private Securities litigation Reform Act of 1995. Investors
are cautioned that such forward-looking statements involve risks and
uncertainties including without limitation the following: (i) the Company's
plans, strategies, objectives, expectations and intentions are subject to change
at any time at the discretion of the Company; (ii) the Company's plans and
results of operations will be affected by the Company's ability to manage its
growth and inventory; (iii) other risks and uncertainties indicated from time to
time in the Company's filings with the Securities and Exchange Commission.
<PAGE 12>
PART II. OTHER INFORMATION
Item 1 -- Legal Proceedings
None.
Item 2 -- Changes in Securities
None.
Item 3 -- Defaults Upon Senior Securities
None.
Item 4 -- Submission of Matters to a Vote of Security Holders
A. The Annual Meeting was held on April 26, 1999.
B. The following individuals were elected Directors at the Meeting and comprise
the entire Board.
Votes for Votes against Votes withheld
--------- ------------- --------------
David W. Clark, Jr. 2,333,309 265,548 778,631
George R. Dunbar 2,333,153 265,704 778,631
Richard Y. Holden, Jr. 2,383,293 215,564 778,631
Walter C. Johnsen 2,383,309 215,548 778,631
Peter H. Kamin 2,383,309 215,548 778,631
Wayne R. Moore 2,333,219 265,638 778,631
Gary D. Pennisten 2,383,309 215,548 778,631
Item 5 -- Other Information
None.
Item 6 -- Exhibits and Reports on Form 8-K
Form 8-K was filed by the Company on April 6, 1999.
<PAGE 13>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ACME UNITED CORPORATION
By /s/ WALTER C. JOHNSEN
------------------------------
Walter C. Johnsen
President and
Chief Executive Officer
Dated: May 10, 1999
By /s/ RONALD P. DAVANZO
------------------------------
Ronald P. Davanzo
Vice President and
Chief Financial Officer
Dated: May 10, 1999
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
Condensed Consolidated Balance Sheet and Condensed Consolidated Statement of
Operations and is qualified in its entirety by reference to such financial
statements.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> MAR-31-1999
<CASH> 549
<SECURITIES> 0
<RECEIVABLES> 8,390
<ALLOWANCES> 200
<INVENTORY> 8,669
<CURRENT-ASSETS> 18,614
<PP&E> 15,723
<DEPRECIATION> 10,117
<TOTAL-ASSETS> 25,520
<CURRENT-LIABILITIES> 12,189
<BONDS> 0
0
0
<COMMON> 8,706
<OTHER-SE> (2,344)
<TOTAL-LIABILITY-AND-EQUITY> 25,520
<SALES> 7,570
<TOTAL-REVENUES> 7,747
<CGS> 6,077
<TOTAL-COSTS> 7,945
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 358
<INCOME-PRETAX> 1,743
<INCOME-TAX> (14)
<INCOME-CONTINUING> (542)
<DISCONTINUED> 2,299
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,757
<EPS-PRIMARY> .52
<EPS-DILUTED> .52
</TABLE>
